

ED COVID-19 TREATMENT PATHWAY

COVID-19 CONFIRMED OR SUSPECTED

1. Severity Assessment

MILD

- No symptoms
- Mild symptoms
- SpO2 > 95% on RA

MODERATE

- SpO2 > 92% at rest on RA
- Desaturation or SOB with mild exertion
- Evidence of LRTI on CXR

SEVERE/CRITICAL

- RR > 30
- SpO2 < 92% at rest on >4 L/min O2 via NP
- HFNO, CPAP or invasive ventilation required

2. Investigations

To be determined as clinically necessary:

Bloods: FBC, UEC, Coag, Troponin, LFTs, CRP, Ca, Mg, ABG, Glucose **Microbiology:** Blood cultures, swabs as appropriate

Imaging: CXR Other: ECG

3. Treatment

MILD TREATMENT

- Inhaled budesonide 800 micrograms BD
- Other medicines (all require senior clinician approval):
 - -Consider sotrovimab
- Consider casirivimab plus imdevimab

See the Statewide Medicines Formulary (Formulary One) for more information (internet).

MODERATE TREATMENT

- Respiratory support:
 - -Aim for SpO2 92-96% for most patients or 88-92% for patients at risk of type 2 respiratory failure
- -Nasal prongs and titrate
- · Position:
 - -Consider awake prone position if desaturating
- Fluid therapy:
- -250 mL x 3 if SBP < 100 mmHg
- -If not responsive, move to severe treatment
- Steroids:
- -Dexamethasone 6 mg IV/PO daily for 10 days (only if O2 requirement)
- -Commence BGL monitoring per Hyperglycaemia Guideline
- Other medicines (all require senior clinician approval):
- -Consider remdesivir
- -Consider casirivimab plus imdevimab
- -Consider baricitinib
- -Consider tocilizumab
- -Consider sarilumab
- VTE prophylaxis

SEVERE TREATMENT

- Respiratory support:
 - -Aim SpO2 > 92%
 - -If RR > 30 or SpO2 < 92% on mask, escalate to HFNO or CPAP
- -Consult ICU
- -Intubation as necessary
- Position:
- -Consider prone position if desaturating
- Fluid therapy:
- -250 mL x 3 if SBP < 100 mmHg
- -Vasopressors if SBP remains < 100 mmHg
- Steroids:
- -Dexamethasone 6 mg IV/PO daily for 10 days
- -Commence BGL monitoring per Hyperglycaemia Guideline
- Other medicines (all require senior clinician approval):
 - -Consider remdesivir
 - -Consider casirivimab plus imdevimab
- -Consider baricitinib
- -Consider tocilizumab
- -Consider sarilumab
- VTE prophylaxis

4. Disposition

SEE RISK ASSESSMENT AND DISPOSITION GUIDELINE